Project Grant R01CA303695
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $695K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
- The National Cancer Institute awarded The Broad Institute, Inc., doing business as Broad Institute of MIT and Harvard, $245,297 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop chimeric molecules that trigger generation of neoantigens from proteins dysregulated in infectious disease and cancer. The molecules will be formed by joining clinical-grade protein binders with reactive groups to generate neoantigens that recruit immune system...
- The National Cancer Institute awarded The Broad Institute, Inc. $651,409 under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2026, to probe cereblon allostery with small molecules as a novel approach to targeted protein degradation for cancer therapy. The research examines how allosteric binding at a newly discovered site on cereblon—an E3 ligase substrate adapter targeted by thalidomide derivatives—can modulate protein recruitment and degradation independently or...
- The National Cancer Institute awarded The Jackson Laboratory $452,458 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to advance and validate single-cell long-read sequencing for cancer molecular profiling. The project develops and validates enhanced tools for single-cell long-read isoform transcriptomics (SCLR-SEQ) to map and analyze full-length spliced isoforms at single-cell resolution in tumor samples. The work addresses technical gaps in current approaches,...
- The National Cancer Institute awarded $237,023 to President and Fellows of Harvard College (operating as Harvard Medical School) on March 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop high-throughput tools for tracking the fate of prematurely terminated transcripts in cancer cells. The research addresses alternative polyadenylation (APA) events—post-transcriptional RNA processing mechanisms that drive oncogenesis independent of DNA mutations—across chronic...
- The National Cancer Institute awarded The Broad Institute, Inc. $439,665 in a Project Grant (R21CA309357) on September 3, 2026, to conduct high-throughput identification of transcription factors that enhance CAR T cell efficacy in solid tumors under the Cancer Biology Research program (CFDA 93.396). The project develops an in vivo screening approach to evaluate transcription factor overexpression in primary human T cells at scale. T cells are lentivirally transduced with a library of all human...
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $443,564 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 2, 2025, with completion by August 31, 2027. The award supports the development of a novel cancer immunotherapy platform utilizing engineered commensal skin bacteria to stimulate tumor-specific T cell immunity. The research focuses on leveraging Staphylococcus epidermidis, a naturally...
- The National Cancer Institute awarded New York Genome Center, Inc. $270,683 on May 5, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and validate Paired-Break-Seq, a single-cell multiomics sequencing technique for joint analysis of single-strand DNA breaks, double-strand DNA breaks, and transcriptome in cancer cells. The work addresses the technical gap in understanding how multiple types of DNA damage interact with gene regulation in heterogeneous tumor environments....
- The National Cancer Institute awarded Chrononai, LLC $399,997 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and commercialize a foundation AI model for live cell phenotyping in cancer research. The recipient will develop a deep learning–based foundation model that integrates cell contour tracking with a time-series transformer architecture to extract dynamic morphodynamic features from live-cell movies and incorporate spatial...
- This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
- The National Cancer Institute awarded Northeastern University $224,400 under the Cancer Biology Research program (CFDA 93.396) on August 1, 2026, to develop a direct RNA sequencing platform that detects dihydrouridine (D) modifications in human lung cancer transcripts at transcriptome-wide, single-nucleotide resolution. Current technologies cannot reliably distinguish dihydrouridine from pseudouridine and uridine, limiting understanding of how uridine modifications regulate RNA biology in...